Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 7/20 | 0.57 |
| ▸ | BTK | Q06187 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | MERTK | Q12866 | 6/20 | 0.51 |
| ▸ | AXL | P30530 | 4/20 | 0.51 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017765 | 0.90 | SYK (0.58) | JAK3BTKMERTKAXLTYRO3 | |
| SCHEMBL25107841 | 0.85 | PTK2 (0.69) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL12085388 | 0.84 | JAK3 (0.73) | JAK3BTKTTKPIK3CBMAPK8 | |
| SCHEMBL25107095 | 0.83 | PTK2 (0.71) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL25107539 | 0.82 | TTK (0.73) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL12085463 | 0.82 | CCNT1 (0.59) | JAK3BTKMERTKPAK4IRAK4 | |
| SCHEMBL17856870 | 0.82 | TTK (0.73) | JAK3BTKTTKPIK3CBMAPK8 | |
| SCHEMBL12085326 | 0.81 | BTK (0.80) | JAK3BTKPTK2LRRK2 | |
| SCHEMBL25107251 | 0.81 | LRRK2 (0.69) | TTKPIK3CBMAPK8PTK2LRRK2 | |
| SCHEMBL30198584 | 0.81 | LRRK2 (0.69) | TTKPIK3CBMAPK8PTK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | JAK3 6/4885BTK 2/4885LMNA 4335/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | JAK3 6/4885BTK 2/4885LMNA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.